Webinar
Precision Medicine Oncology
calendar

July 12, 2023

Calendar
clock

12:00PM - 1:00PM

(GMT+0000)

Register

View all IQVIA events

Precision oncology is becoming mainstream in clinical practice and research, driving the development of high-technology diagnostics and innovative treatments. Targetable molecular alterations enable treatment individualism and lead to increase of treatment efficacy.

Join us as we explore the evolving landscape of biomarkers and their impact on oncology markets across different tumor types and geographies. In addition, we will uncover the fundamentals of immunotherapies in oncology, as we welcome Lien Lybaert, CEO of Persomed, who will join us to share her immunotherapy expertise and unveil the groundbreaking development of a cancer vaccine for colorectal cancer.

3 Key Takeaways

  • Navigate the complexities of biomarker testing
  • Learn how biomarkers are tracked using IQVIA’s syndicated oncology offering
  • Explore genomics in the immuno-oncology landscape
Speakers:

Vladimir Bonesvski

Associate Director, Global Oncology Product & Strategy, IQVIA

Vladimir works as Associate Director at IQVIA and is responsible for product & strategy for our Global Oncology group.

Prior to moving to his current position, Vladimir was Country Commercial Lead with IQVIA, responsible for all commercial activities in Croatia. Before joining IQVIA, he gained oncology experience with the pharmaceutical industry and held various positions within sales, marketing and business development. Overall, Vladimir has more than 22 years of pharmaceutical industry experience.

Vladimir holds a Master of Pharmacy degree from Zagreb University, as well as a Master’s degree in Health Economics and Pharmacoeconomics from Pompeu Fabra University in Barcelona.

Kriti Jindal

Client Service Manager, Global Oncology, IQVIA

Kriti Jindal is a Client Service manager in the Global Oncology team at IQVIA London. She has been a part of this team for 4 years. Kriti is a specialist in IQVIA’s syndicated oncology patient data. In her current role, she is responsible for understanding project requirements, developing fit for purpose solutions, and executing & delivering end to end projects, using IQVIA’s syndicated offering ‘Oncology Dynamics’. Kriti has participated in many poster presentations at international congresses, such as ESMO, ASCO, and ASH.

Prior to this role, she has worked for 3 years as a custom market research consultant at IQVIA. In this position, she gained experience in different therapy areas through projects spanning market assessment, market access, digital health, and social media listening. Kriti also has knowledge of consumer goods market and wet-lab R&D from her previous work experiences.

Lien Lybaert

CEO, Persomed

Lien studied pharmaceutical sciences where she focused on targeted cancer therapy in her master thesis. After her studies, she did an IWT-funded PhD in the lab of Biopharmaceutical Technology of Prof. Bruno De Geest at Ghent University where she focused on the design of immune-modulating generic polymeric strategies for personalised cell-based cancer vaccination. During her PhD she went abroad as FWO-funded visiting researcher in the lab of Prof. Aaron Esser-Kahn at the University of California, Irvine where she researched TLR-ligand adjuvant functionalisation of cancer vaccines.

Lien is scientific and clinical alliance manager at myNEO where her expertise in the immune-oncology field as well as her in-depth knowledge of tumour immuno-biology and therapeutic strategies, make her the link between the bioinformatics team, the collaborating laboratories, hospitals, and universities as well as the partners of myNEO.Lien is also acting interim CEO of Persomed where she manages and coordinates the investment round and the preparation for the clinical phase I in metastatic colorectal cancer patients.

Related solutions

Contact Us